Delivering Better Outcomes

OmniNano Pharmaceuticals is a developmental stage, start-up company, based in the greater Houston area, Texas. Built upon patented nano-drug delivery platform technology that co-delivers two therapeutical agents with two distinctively different mechanisms of action, our goal is to significantly improve the efficacy, while reduce the toxicity for treating solid tumors.

Currently, we are focusing on advancing our proprietary drug delivery system for treating pancreatic cancer (pancreatic ductal adenocarcinoma, PDAC). PDAC is a devastating disease with an extremely poor 5-year survival rate (12.5%). Our lead drug candidate, ONP-001, consists of novel polymeric micelles encapsulating two naturally occurring drug compounds: one is an FDA-approved chemotherapeutic drug and the other is capable of depleting cancer stem cells and modulating tumor stroma to overcome drug resistance, enhance drug delivery efficiency, and display significant antitumor activity on preclinical PDAC models.

Our efforts have been supported in funding by CPRIT (Cancer Prevention and Research Institute of Texas) to perform IND-enabling studies and developmental work of ONP-001.